Weight Loss Injectables: Separating Fact from the Most Common Myths

Both licensed UK injectables (tirzepatide and semaglutide) are once-weekly subcutaneous injections given via a pre-filled pen; no clinic visit is needed for the injection itself.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1); semaglutide activates one (GLP-1 only), a biological difference that influences the trial results for each.
Side effects are mostly gastrointestinal, typically most noticeable after starting or after a dose increase, and often settle within the first week or two.
Because these are prescription-only medicines, any seller offering them without a clinical assessment is operating outside UK law, the MHRA has warned publicly about counterfeit pens causing serious harm.

Weight loss injectables licensed in the UK are once-weekly, self-administered medicines — tirzepatide (Mounjaro) and semaglutide (Wegovy) — that work by acting on gut hormones to reduce appetite and slow gastric emptying. They are prescription-only medicines; a prescriber assesses clinical suitability before any treatment begins. If you've arrived here feeling overwhelmed by competing claims online, that reaction is entirely reasonable: this area attracts a lot of noise. What follows is the evidence, plainly stated.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The evidence, the process and the honest safety picture for injectables used in weight management

The biggest myth: that injectables are a shortcut requiring no medical oversight

The most persistent misconception about weight loss injectables is that they sit somewhere between a supplement and a cosmetic treatment, something you pick up, use for a few weeks and stop. They do not. Tirzepatide and semaglutide are classified as Prescription-Only Medicines under UK law, which means a registered prescriber must assess whether they are clinically appropriate for you before a single pen is dispensed. That assessment is not a formality; it considers your BMI, existing health conditions, current medicines, and whether this class of drug is safe for you specifically.

The MHRA has been unambiguous about the risks of bypassing that step. Counterfeit pens sold on social media and from unverified online sellers have, in documented cases, contained insulin rather than the stated active ingredient, with serious consequences for the people who used them. If you are researching where to buy weight loss injections in the UK, verifying that any pharmacy you use is registered on the GPhC register at pharmacyregulation.org is the single most important safety check you can do.

The licensed route is not more complicated, it is simply a proper clinical consultation, a prescriber's review, and then the medicine dispensed from a pharmacy in an authenticated supply chain.

How weight loss injectables actually work, and why the dose starts low

Both licensed injectables mimic hormones your gut releases after eating. Semaglutide targets the GLP-1 receptor, which signals fullness to the brain and slows how quickly the stomach empties. Tirzepatide does the same and also activates the GIP receptor, making it the only dual-agonist weight management medicine currently licensed in the UK. You can read more about how each medicine differs on our injectable weight loss drug overview.

Treatment always starts at the lowest strength (2.5 mg for tirzepatide, 0.25 mg for semaglutide) not because those doses drive meaningful weight loss, but because starting low gives your body time to adjust and significantly reduces early nausea. The prescriber then titrates upward, typically in four-week steps, to the highest dose you tolerate well. The titration schedule is set by your prescriber and the Patient Information Leaflet; nobody should be adjusting doses based on a forum recommendation.

In clinical trials, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks in SURMOUNT-1, a trial of 2,539 adults with obesity. Semaglutide 2.4 mg produced around 15% average loss over 68 weeks in the STEP 1 trial. Both figures come from participants following a reduced-calorie diet and increased activity alongside the medicine, the injections support lifestyle change, they do not replace it. The SURMOUNT-1 paper in the New England Journal of Medicine gives the full methodology for anyone who wants to read the source directly.

Side effects worth knowing about before your first pen

The side-effect profile of weight loss injectables is dominated by the gastrointestinal system: nausea, loose stools, constipation, indigestion and burping are the most reported. Most people find these are worst in the early weeks and after each dose step up, then ease. Staying well hydrated, eating smaller portions more slowly, and avoiding very fatty or spicy meals during the adjustment period all help, though your prescriber is the right person to advise on your specific situation.

Some effects need prompt medical attention. The NHS tirzepatide page lists red flags clearly: severe, persistent stomach pain that reaches through to the back (which can signal pancreatitis), signs of a serious allergic reaction, and symptoms of gallbladder problems. These are uncommon, but the rule is simple, if in doubt, contact a clinician the same day rather than waiting.

Women using oral contraceptives starting tirzepatide should add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. The equivalent concern has not been demonstrated for semaglutide. Our guide to weight loss injections covers practical considerations including contraception, storage and injection technique in more detail.

Who these medicines are licensed for, and how the NHS and private routes differ

The private licensed eligibility criteria, set by the medicines' marketing authorisations, cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI is a starting point, not the whole picture; prescribers weigh the full clinical assessment before approving treatment.

NHS access is narrower and phased. NICE's appraisal of tirzepatide (TA1026) recommends it for BMI 35 and above alongside specific comorbidities, rolled out in cohorts from June 2025. Wegovy on the NHS is routed through specialist weight management services with typically long waiting lists. For people who meet the private criteria but cannot access NHS treatment (or simply prefer not to wait) a regulated private pharmacy is the lawful alternative. Our treatment page explains what a consultation with our prescribers covers and how the process works from start to delivery.

Every pen dispensed by a GPhC-registered pharmacy arrives from the licensed UK supply chain. That matters because it is the only way to be certain the product in your hands is genuine. If you are still building an understanding of how a weight loss injectable fits into a broader treatment plan, that page brings together the key clinical context in one place. Curious about which specific injectables are available and how they compare? Our overview of weight loss injectable names sets out the licensed options clearly. For the practical side of using a pen (injection sites, technique and what to do with used needles) the injectable pen guide is worth a read before you start.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions